<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.109318</article-id><article-id pub-id-type="publisher-id">ACM-37792</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200900000_90151593.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  大细胞神经内分泌宫颈癌1例报告附文献复习
  Large Cell Neuroendocrine Cervical Cancer: A Case Report with Literature Review
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>钊</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>罗</surname><given-names>琰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>齐</surname><given-names>卫卫</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>艺璇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吕</surname><given-names>静</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院肿瘤化疗科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>09</month><year>2020</year></pub-date><volume>10</volume><issue>09</issue><fpage>2117</fpage><lpage>2120</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：报告1例罕见的大细胞神经内分泌宫颈癌并结合文献讨论其诊断及治疗方法。方法：以病例报告的方式，结合国外文献复习，综合分析大细胞神经内分泌宫颈癌的诊断及治疗。结果：大细胞神经内分泌的诊断主要以组织病理学为依据，以手术治疗、化疗、放疗、内分泌治疗、靶向治疗或免疫治疗为主要治疗方法。结论：大细胞神经内分泌宫颈癌的诊断需排除其他宫颈原发疾病，以手术治疗为主，根据组织病理学特性选择合适的辅助治疗。
    Objective: To report a rare case of large cell neuroendocrine cervical cancer and discuss its diagnosis and treatment methods based on literature. Methods: The diagnosis and treatment of large-cell neuroendocrine cervical cancer were comprehensively analyzed in the form of case reports, combined with review of foreign literature. Results: The diagnosis of large cell neuroendocrine was mainly based on histopathology, with surgical treatment, chemotherapy, radiotherapy, endocrine therapy, targeted therapy or immunotherapy as the main treatment methods. Conclusion: The diagnosis of large-cell neuroendocrine cervical cancer should exclude other primary cervical diseases, and focus on surgical treatment, and choose appropriate adjuvant treatments according to histopathological characteristics. 
  
 
</p></abstract><kwd-group><kwd>宫颈癌，大细胞神经内分泌，诊断，治疗, Cervical Cancer</kwd><kwd> Large Cell Neuroendocrine</kwd><kwd> Diagnosis</kwd><kwd> Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：报告1例罕见的大细胞神经内分泌宫颈癌并结合文献讨论其诊断及治疗方法。方法：以病例报告的方式，结合国外文献复习，综合分析大细胞神经内分泌宫颈癌的诊断及治疗。结果：大细胞神经内分泌的诊断主要以组织病理学为依据，以手术治疗、化疗、放疗、内分泌治疗、靶向治疗或免疫治疗为主要治疗方法。结论：大细胞神经内分泌宫颈癌的诊断需排除其他宫颈原发疾病，以手术治疗为主，根据组织病理学特性选择合适的辅助治疗。</p></sec><sec id="s2"><title>关键词</title><p>宫颈癌，大细胞神经内分泌，诊断，治疗</p></sec><sec id="s3"><title>Large Cell Neuroendocrine Cervical Cancer: A Case Report with Literature Review</title><p>Zhao Liu<sup>*</sup>, Yan Luo<sup>*</sup>, Weiwei Qi, Yixuan Wang, Jing Lv<sup>#</sup></p><p>Department of Tumor Chemotherapy, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/38-1571587x4_hanspub.png" /></p><p>Received: Sep. 2<sup>nd</sup>, 2020; accepted: Sep. 17<sup>th</sup>, 2020; published: Sep. 24<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/38-1571587x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To report a rare case of large cell neuroendocrine cervical cancer and discuss its diagnosis and treatment methods based on literature. Methods: The diagnosis and treatment of large-cell neuroendocrine cervical cancer were comprehensively analyzed in the form of case reports, combined with review of foreign literature. Results: The diagnosis of large cell neuroendocrine was mainly based on histopathology, with surgical treatment, chemotherapy, radiotherapy, endocrine therapy, targeted therapy or immunotherapy as the main treatment methods. Conclusion: The diagnosis of large-cell neuroendocrine cervical cancer should exclude other primary cervical diseases, and focus on surgical treatment, and choose appropriate adjuvant treatments according to histopathological characteristics.</p><p>Keywords:Cervical Cancer, Large Cell Neuroendocrine, Diagnosis, Treatment</p><disp-formula id="hanspub.37792-formula33"><graphic xlink:href="//html.hanspub.org/file/38-1571587x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/38-1571587x8_hanspub.png" /> <img src="//html.hanspub.org/file/38-1571587x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>子宫颈的神经内分泌肿瘤是一组罕见的恶性肿瘤，其特征是侵袭性和易于早期转移性。但是神经内分泌肿瘤仅占所有子宫颈癌的5% [<xref ref-type="bibr" rid="hanspub.37792-ref1">1</xref>]。大细胞神经内分泌癌(LCNC)的发生更为罕见，迄今为止只报道了近70例左右 [<xref ref-type="bibr" rid="hanspub.37792-ref2">2</xref>]。此外，宫颈大细胞神经内分泌癌的组织学标准为存在大量细胞质的大细胞，具有突出核仁的囊泡核和高有丝分裂率。LCNC的生长模式主要见于岛状、类器官、小梁或固体模式，通常伴有周边栅栏装排或花环形成，以及局灶性肿瘤坏死。免疫组化神经内分泌标记物包括突触素，嗜铬粒蛋白，CD56和神经元特异性烯醇化酶(NSE)。LCNC中嗜铬粒蛋白的免疫组织化学阳性率为87%，突触素为56%，嗜铬粒蛋白，突触素或NSE中的至少一种为88% [<xref ref-type="bibr" rid="hanspub.37792-ref3">3</xref>]。该报告描述了大细胞神经内分泌癌的罕见表现。</p></sec><sec id="s6"><title>2. 病例资料</title><p>患者女性，33岁。4余年前(2016-3)无明显诱因出现阴道不规则流血，量少，色暗红，未予特殊诊治。2016-5-4行宫颈活检取病理：(宫颈5点、宫颈12点、宫颈管)慢性子宫颈炎，部分区域复鳞上皮呈高级别上皮内病变(CINIII级)，其中(5点)局灶区域有浸润(组织挤压较重，细胞变形)；免疫组化示(宫颈5点、12点)：p16弥漫(+)。2016-05-14行专科检查见：宫颈重度糜烂状，见直径约2 cm肿物，接触性出血阳性。遂行1周期IP方案化疗：伊立替康240 mg d1 + 顺铂100 mg d1，过程顺利。1周期化疗后复查妇科B超：宫颈后壁混合回声，符合宫颈癌。2016-06-14于黄岛妇科行“腹腔镜下子宫根治性切除 + 双侧输卵管切除 + 左侧卵巢囊肿剥除 + 右侧卵巢活检 + 双侧卵巢移位 + 盆腔淋巴结根治性切除 + 肠粘连松解术”。术中见：肠管与侧腹壁呈广泛粘连，子宫体大小正常，表面光滑，与周围无粘连，左侧卵巢内见囊性肿物，直径约2 cm，其内为清亮液体，盆腔淋巴结可扪及数个肿大。术中冰冻病理：1) 子宫颈低分化癌，结合免疫组化结果，意见为大细胞神经内分泌癌(大小2.5 * 2 cm)，侵犯宫颈纤维肌层全层，未累及宫颈管内口、阴道壁断端及左、右宫旁组织，左侧盆腔(0/7)及右侧盆腔(0/6)淋巴结内未见癌转移；2) 增殖期状态子宫内膜；3) (双侧)输卵管未见癌累及；4) (左、右)子宫血管腔内未见癌栓；免疫组化：Syn(+)、CgA(+)、CD56(+)、p40(−)、CK5/6(−)、Ki-67阳性率约50%，经CD31、D2-40染色间质脉管内可见癌栓，S-100示神经侵犯(+)。于2016-8-11行术后第1周期IP方案化疗：伊立替康280 mg d1 + 顺铂100 mg d1，后于2016-9-1~2016-10-11行盆腔放疗，5225cGY/25f (5野调强)。放疗后因患者白细胞及中性粒细胞较低且存在贫血，2016-12-04、2017-1-2行第2、3周期化疗(单药顺铂)：顺铂50 mg d1-2，过程顺利。后因骨髓抑制终止化疗。定期复查无异常。2017-07-15胸部CT平扫示：左肺斜裂处、左肺下叶靠近斜裂处、右肺中上叶结节影，较前增大。2017-11-20复查胸部CT平扫示：双肺多发结节，较前增多、部分略增大，考虑转移瘤可能性大。后于2017-12-16至2018-3-17行4周期EP方案化疗：依托泊苷0.15 gd1-2，0.12 gd3 + 顺铂50 mgd1-2化疗，2018-04-20胸部CT平扫：双肺多发结节，部分较前略增大。患者拒绝化疗，后定期复查，于2018-11-16开始口服安罗替尼12 mg qd，服用14天，休7天，共完成8周期治疗，最后服药时间2019-04-10。后定期复查胸部CT，2019-05-14胸部CT平扫：双肺多发转移瘤复查，部分病灶较前略增大，纵隔多发肿大淋巴结；2019-06-18和2019-8-16胸部CT平扫：双肺多发转移瘤复查，部分病灶较前略增大，纵隔内多发肿大淋巴结，部分较前减小。后患者因腹泻，于2019-10-6停药至今。2020-3-12将手术标本送先声基因检测公司行GNC检测：PDL-1(−)；TMB3.68Muts/Mb；MSS；未见有意义的基因突变。行奥曲肽受体检测呈阳性，于2020-4-16行第1次奥曲肽微球20 mg肌注，无明显不适。2020-4-30出现憋气加重、肝功异常，CT示双肺、肝内病灶增多，考虑病情进展。于2020-5-9开始以白蛋白型紫杉醇 + 顺铂化疗，目前已完成2周期。化疗后症状明显好转，肝功恢复正常。</p></sec><sec id="s7"><title>3. 讨论</title><p>大多数子宫颈大的神经内分泌肿瘤病例都是在早期诊断为阴道出血或定期进行骨盆检查。此外，鉴于有报道说LCNC在组织学上已被诊断为混合型，并与小细胞神经内分泌癌，腺癌或鳞状细胞癌共存，因此本例强调了在可能的情况下进行适当大小的活检以确保准确诊断的重要性 [<xref ref-type="bibr" rid="hanspub.37792-ref3">3</xref>]。同样，检查人乳头瘤病毒(HPV)的状态以及对LCNC患者的肿瘤行为和对治疗反应的影响也很有趣。不幸的是，该信息不适用于我们的患者。Grayson等。在12例大型神经内分泌肿瘤中，有7例发现HPV呈阳性，这表明病毒感染与这种罕见但侵袭性肿瘤之间存在潜在的联系 [<xref ref-type="bibr" rid="hanspub.37792-ref4">4</xref>]。因此，常规临床筛查的生命力以及临床医生要注意这种差异在这种恶性肿瘤的早期发现和管理中至关重要。在这种情况下要注意的另一个临床特征是，没有转移性神经内分泌肿瘤患者常见的潮红，呼吸急促和腹泻等常规症状。这表明尽管这些特征的存在应引起我们更高的临床怀疑，但它们的缺失并不排除神经内分泌肿瘤。</p><p>神经内分泌癌是具有高转移潜力的侵袭性肿瘤。他们经常被误诊，通常与预后不良有关 [<xref ref-type="bibr" rid="hanspub.37792-ref5">5</xref>]。而且，这是一种罕见的诊断。因此，治疗方法主要是根据肺神经内分泌肿瘤的治疗方法进行调整的 [<xref ref-type="bibr" rid="hanspub.37792-ref6">6</xref>]。尽管手术在延长生存期中的作用是有争议的，但化学疗法是针对它的主要治疗选择。可用的大多数化疗选择包括卡铂和依托泊苷(我们的患者均使用了这两种药物)。其他常用组合包括环磷酰胺，阿霉素和长春新碱。 Embry等人的多元分析。结果表明，在癌症治疗的任何时候加入化学疗法都可以延长生存期 [<xref ref-type="bibr" rid="hanspub.37792-ref7">7</xref>]。然而，疾病的早期阶段与更好的生存有关。IV期癌症的平均总生存期为1.5个月。我们的患者在诊断后四个月存活。</p></sec><sec id="s8"><title>4. 结论</title><p>总之，该病例报告揭示了子宫颈罕见的侵袭性恶性肿瘤，这种恶性肿瘤常常被误诊并伴有不良的预后。从今以后，我们想强调在评估潜在的恶性肿瘤时考虑将神经内分泌肿瘤作为鉴别因素的重要性，以帮助其识别和在较早阶段探索治疗方案。</p><p>注：该病例报道已获得病人的知情同意。</p></sec><sec id="s9"><title>文章引用</title><p>刘 钊,罗 琰,齐卫卫,王艺璇,吕 静. 大细胞神经内分泌宫颈癌1例报告附文献复习Large Cell Neuroendocrine Cervical Cancer: A Case Report with Literature Review[J]. 临床医学进展, 2020, 10(09): 2117-2120. https://doi.org/10.12677/ACM.2020.109318</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37792-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Wang, K.L., Wang, T.Y., Huang, Y.C., Lai, J.C., Chang, T.C. and Yen, M.S. (2009) Human Papillomavirus Type and Clinical Manifestation in Seven Cases of Large-Cell Neuroendocrine Cervical Carcinoma. Journal of the Formosan Medical Association, 108, 428-432. &lt;br&gt;https://doi.org/10.1016/S0929-6646(09)60088-7</mixed-citation></ref><ref id="hanspub.37792-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Nishio, Y., Miyatake, T., Yasuoka, H., et al. (2017) Primary Neuroendocrine Carcinoma of the Uterine Cervix Treated with Complete Surgical Resection and Adjuvant Combination Chemotherapy. Journal of Clinical Gynecology and Obstetrics, 6, 23-27. &lt;br&gt;https://doi.org/10.14740/jcgo432w</mixed-citation></ref><ref id="hanspub.37792-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Rekhi, B., Patil, B., Deodhar, K.K., et al. (2013) Spectrum of Neuroendocrine Carcinomas of the Uterine Cervix, Including Histopathologic Features, Terminology, Immunohistochemical Profile, and Clinical Outcomes in a Series of 50 Cases from a Single Institution in India. Annals of Diagnostic Pathology, 17, 1-9.  
&lt;br&gt;https://doi.org/10.1016/j.anndiagpath.2012.01.009</mixed-citation></ref><ref id="hanspub.37792-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Grayson, W., Rhemtula, H.A., Taylor, L.F., Allard, U. and Tiltman, A.J. (2002) Detection of Human Papillomavirus in Large Cell Neuroendocrine Carcinoma of the Uterine Cervix: A Study of 12 Cases. Journal of Clinical Pathology, 55, 108-114. &lt;br&gt;https://doi.org/10.1136/jcp.55.2.108</mixed-citation></ref><ref id="hanspub.37792-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Krivak, T.C., McBroom, J.W., Sundborg, M.J., Crothers, B. and Parker, M.F. (2001) Large Cell Neuroendocrine Cervical Carcinoma: A Report of Two Cases and Review of the Literature. Gynecologic Oncology, 82, 187-191.  
&lt;br&gt;https://doi.org/10.1006/gyno.2001.6254</mixed-citation></ref><ref id="hanspub.37792-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Li, W.W., Yau, T.N., Leung, C.W., Pong, W.M. and Chan, M.Y. (2009) Large-Cell Neuroendocrine Carcinoma of the Uterine Cervix Complicating Pregnancy. Hong Kong Medical Journal, 15, 69-72.</mixed-citation></ref><ref id="hanspub.37792-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Embry, J.R., Kelly, M.G., Post, M.D. and Spillman, M.A. (2011) Large Cell Neuroendocrine Carcinoma of the Cervix: Prognostic Factors and Survival Advantage with Platinum Chemotherapy. Gynecologic Oncology, 120, 444-448.  
&lt;br&gt;https://doi.org/10.1016/j.ygyno.2010.11.007</mixed-citation></ref></ref-list></back></article>